Open AccessTiming of erythropoietin modified mesenchymal stromal cell transplantation for the treatment of experimental bronchopulmonary dysplasia
Author(s) -
Zhang Zhaohua,
Sun Chao,
Wang Jue,
Jiang Wen,
Xin Qian,
Luan Yun
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13843
Subject(s) - erythropoietin , mesenchymal stem cell , bronchopulmonary dysplasia , transplantation , medicine , p38 mitogen activated protein kinases , inflammation , apoptosis , mapk/erk pathway , cancer research , stromal cell , immunology , andrology , pathology , biology , kinase , microbiology and biotechnology , pregnancy , biochemistry , genetics , gestational age
The aim of this study is to optimize the timing of erythropoietin gene modified mesenchymal stem cells (EPO‐MSCs) transplantation for bronchopulmonary dysplasia ( BPD ). Three weeks post‐operation, the results indicated that the damage of airway structure and apoptosis were significantly decreased, the proliferation was increased in three EPO ‐ MSC s transplantation groups as compared with BPD mice. Moreover, the inflammation cytokines were improvement in early EPO ‐ MSC s injection mice than in BPD mice, but there was no significant difference between late injection and BPD groups. Furthermore, the protein expression ratio of p‐p38/p38 MAPK was down‐regulation in early mice but not in late transplantation mice. Our findings suggest that EPO ‐ MSC s maybe attenuate BPD injury in early than in late administration by inhibiting inflammation response through down‐regulation of the p38 MAPK signalling pathway.